2-(Alkyl/Aryl)amino-6-benzylpyrimidin-4(3 H)-ones as inhibitors of wild-type and mutant HIV-1: Enantioselectivity studies

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3558-3562

  Rotili, Dante ^a   Samuele, Alberta ^b   Tarantino, Domenico ^a   Ragno, Rino ^a   Musmuca, Ira ^a   Ballante, Flavio ^a   Botta, Giorgia ^a   Morera, Ludovica ^a   Pierini, Marco ^a   Cirilli, Roberto ^c   Nawrozkij, Maxim B ^d   Gonzalez, Emmanuel ^e   Clotet, Bonaventura ^e   Artico, Marino ^a   Esté, José A ^e   Maga, Giovanni ^b   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d VOLGOGRAD STATE TECHNICAL UNIVERSITY   (Russian Federation)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 [ 1 ( 2,6 DIFLUOROPHENYL)ETHYL] 5 METHYL 2 (METHYL N PROPYLAMINO) 3H PYRIMIDIN 4 ONE; ARGININE; DAPIVIRINE; EFAVIRENZ; ENZYME; LYSINE; MC 1501; MC 2082; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; RACEMIZATION; VIRUS MUTANT; WILD TYPE;

ANTI-HIV AGENTS; BENZENE DERIVATIVES; CELL LINE; ENZYME ASSAYS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; MUTATION; PYRIMIDINONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859804994     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201308v     Document Type: Article

References (13)

1. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3, 4-dihydro-5-alkylpyrimidin-4(3 H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase J. Med. Chem. 2001, 44, 2544-2554
2. Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P. 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3 H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family Bioorg. Med. Chem. 2005, 13, 2065-2077
3. Mai, A.; Artico, M.; Rotili, D.; Tarantino, D.; Clotet-Codina, I.; Armand-Ugon, M.; Ragno, R.; Simeoni, S.; Sbardella, G.; Nawrozkij, M. B.; Samuele, A.; Maga, G.; Este, J. A. Synthesis and biological properties of novel 2-aminopyrimidin-4(3 H)-ones highly potent against HIV-1 mutant strains J. Med. Chem. 2007, 50, 5412-5424
4. Johnson, L. B.; Saravolatz, L. D. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor Clin. Infect. Dis. 2009, 48, 1123-1128
5. de Bethune, M. P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antiviral Res. 2010, 85, 75-90
6. Rotili, D.; Tarantino, D.; Artico, M.; Nawrozkij, M. B.; Gonzalez-Ortega, E.; Clotet, B.; Samuele, A.; Este, J. A.; Maga, G.; Mai, A. Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level J. Med. Chem. 2011, 54, 3091-3096
7. Rodriguez-Barrios, F.; Balzarini, J.; Gago, F. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations J. Am. Chem. Soc. 2005, 127, 7570-7578
8. Geitmann, M.; Unge, T.; Danielson, U. H. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance J. Med. Chem. 2006, 49, 2375-2387
9. Geitmann, M.; Unge, T.; Danielson, U. H. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors J. Med. Chem. 2006, 49, 2367-2374
10. Ortiz, A. R.; Pisabarro, M. T.; Gago, F.; Wade, R. C. Prediction of drug binding affinities by comparative binding energy analysis J. Med. Chem. 1995, 38, 2681-2691
11. Gonzalez, E.; Ballana, E.; Clotet, B.; Este, J. A. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP) AIDS 2011, 25, 1557-1583
12. Gonzalez-Ortega, E.; Mena, M. P.; Permanyer, M.; Ballana, E.; Clotet, B.; Este, J. A. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation Antimicrob. Agents Chemother. 2010, 54, 4487-4492
13. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions J. Mol. Biol. 1997, 274, 738-747